18 July 2023 - The DoH has chosen to publish another version after the event.

Version 4 of the agenda for the July 2023 PBAC meeting includes the following changes:

• Budesonide (Jorveza) - new resubmission
• Daprodustat (Jesduvroq) – to be considered at future PBAC meeting
• Foslevodopa with foscarbidopa (Vyalev) - to be considered at a future PBAC meeting
• Niraparib tosylate monohydrate (Zejula) - new resubmission
• Olaparib (Lynparza) - new resubmission
• Ravulizumab (Ultomiris) - new resubmission
• Tirzepatide (Mounjaro) – revised formulations
  
• Trabectedin (Yondelis) – review of positive PBAC recommendations not accepted by applicants – withdrawn, listing arrangements under consideration